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Abstract
Purpose To determine the safety of fluconazole in neonates
and other paediatric age groups by identifying adverse events
(AEs) and drug interactions associated with treatment.
Methods A search of EMBASE (1950–January 2012),
MEDLINE (1946–January 2012), the Cochrane database
for systematic reviews and the Cumulative Index to Nursing
and Allied Health Literature (1982–2012) for any clinical
study about fluconazole use that involved at least one pae-
diatric patient (≤17 years) was performed. Only articles with
sufficient quality of safety reporting after patients’ exposure
to fluconazole were included.
Results We identified 90 articles, reporting on 4,209
patients, which met our inclusion criteria. In total, 794
AEs from 35 studies were recorded, with hepatotoxicity
accounting for 378 (47.6 %) of all AEs. When fluconazole
was compared with placebo and other antifungals, the
relative risk (RR) of hepatotoxicity was not statistically
different [RR 1.36, 95 % confidence interval (CI) 0.87–
2.14, P=0.175 and RR 1.43, 95 % CI 0.67–3.03,
P=0.352, respectively]. Complete resolution of hepatoxicity
was achieved by 84 % of patients with follow-up available.
There was no statistical difference in the risk of gastrointes-
tinal events of fluconazole compared with placebo and other
antifungals (RR 0.81, 95 % CI 0.12–5.60, P =0.831 and RR
1.23, 95 %CI 0.87–1.71, P=0.235, respectively). There
were 41 drug withdrawals, 17 (42 %) of which were due
to elevated liver enzymes. Five reports of drug interactions
occurred in children.
Conclusion Fluconazole is relatively safe for paediatric
patients. Hepatotoxicity and gastrointestinal toxicity are
the most common adverse events. It is important to be aware
that drug interactions with fluconazole can result in signif-
icant toxicity.
Keywords Fluconazole . Safety . Neonates . Paediatrics .
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Background
Invasive candidiasis is associated with high morbidity and
mortality in neonates and children, with the highest inci-
dence in premature neonates. Studies in neonates have
shown an incidence rate of 2–28 % depending on birth
weight [1]. Amphotericin B is the drug of choice for the
treatment of invasive candidiasis; however, nephrotoxicity
has been associated with this drug [2]. Fluconazole remains
a suitable alternative and has also been used routinely as
prophylaxis for very low birth weight neonates and children
with other risk factors. Risk factors in neonates include
prematurity, broad spectrum antibiotics, central venous cath-
eter, mechanical ventilation, use of H2 receptor antagonists
and parenteral nutrition. Immunosuppression from endogenous
or exogenous causes, such as cystic fibrosis, malignancy,
drug therapy (cytotoxics, corticosteroids, immunosuppressives),
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haematological diseases, organ or bone marrow transplanta-
tion and prolonged intensive care, are factors in paediatric
patients beyond the neonatal period [3, 4].
Fluconazole, a bis-triazole broad spectrum antifungal
agent discovered by Richardson et al. during a programme
initiated by Pfizer Central Research in 1978 [5], is a suitable
alternative to amphotericin B. It is available as an oral tablet,
oral suspension and intravenous formulation. Its antifungal
activity is achieved by preventing fungal membrane sterol
synthesis through the inhibition of cytochrome P450 (CYP)-
dependent lanosterol C-14α-demethylase conversion of
lanosterol to ergosterol, resulting in an impairment of
fungal cell replication. Although CYP is also present in
mammalian cells, fluconazole is highly selective for fungal
CYP [6, 7].
Fluconazole is well absorbed orally with extensive bio-
availability, and most of the drug is excreted unchanged in
the urine; only 11 % is excreted as metabolites, while a
small percentage is excreted in the faeces. The elimination
half-life of the drug is about 30 h (range 20–50 h), with a
faster rate of elimination in older children than adults. In
neonates, however, the mean plasma elimination half-life is
longer (55–90 h) [8–10].
Fluconazole is licensed in children for mucosal candidi-
asis, invasive candidiasis and prophylaxis against candidal
infections in immunocompromised patients. Common
adverse reactions ascribed to the drug from clinical trials
include deranged liver enzymes, cholestasis, headache, skin
rash and gastrointestinal symptoms [11].
Due to the increasing use of the drug as prophylaxis and for
the treatment of fungal infections in paediatric and neonatal
patients, as well the need to identify toxicity associated with
treatment, we decided to undertake a systematic review of
safety data published on fluconazole in these populations.
Method
Search strategy
We searched MEDLINE (1946–January 2012), EMBASE
(1950–January 2012), the Cochrane database for systematic
reviews, Cumulative Index to Nursing and Allied Health
Literature (CINAHL1982–January 2012) and the Cochrane
library (Cochrane Central Register of Controlled Trials,
Cochrane database of systematic reviews, and Database of
abstracts of reviews of effects) for any clinical study about
fluconazole use that involved at least one paediatric patient
(≤17 years). Any study with involvement of a paediatric age
group participant taking at least a single dose of fluconazole
was eligible. Only studies with a report of safety after
exposure to fluconazole in the paediatric patients were
included. There was no restriction on the language of
publication of the articles as translations to extract relevant
data were done; where translations were not possible,
abstracts containing relevant data were used. Also included
in this review were any clinical study, whether comparative
or non-comparative, randomised controlled trials (RCTs) or
case reports and also letters to the editors that documented
exposure of a paediatric patient to fluconazole and reported on
safety. Included articles and extracted data were validated by
two reviewers. Search terms comprised free text words and
subject headings. These included terms relating to azole or
imidazole or fluconazole, adverse effects or adverse drug reac-
tions or side effects, pharmacokinetics and drug interactions.
Data extraction
Data extracted from each study included the year of publi-
cation, type of study, number of paediatric patients exposed,
age of paediatric patients exposed, doses of fluconazole
used, route of administration and safety data. The safety
data extracted were occurrence of any adverse event (AE),
any drug interactions, any withdrawal due to AEs and any
drug-related death.
Data quality assessment
To minimise the risk of bias, we assessed the quality of
included RCTs using the CONSORT checklist for reporting
of harm [12]. All RCTs with scores of ≥6 out of nine criteria
were considered to provide good quality safety reporting.
Cohort studies were scored using the STROBE checklist
[13], where a score of >70 % is considered to be good. Case
series were evaluated using the health technology assess-
ment checklist [14], and all studies fulfilling the good or
satisfactory criteria were included.
Data collection
The relevant data were extracted onto the data extraction
form. Participants in the study were grouped into paediatric
age groups of preterm neonates (<36 weeks gestation, 0–
27 days), full-term neonates (0–27 days, >37 weeks gesta-
tion), infants and toddlers (28 days–23 months), children
(2–11 years) and adolescents (12–17 years). All reported
AEs were pooled together from the various studies. The
duration of treatment was grouped into <21, 21–42 and
>42 days; the treatment dose was grouped into <3, 3–6
and >6 mg/kg; the route of administration was recorded as
intravenous (IV), oral or IV and oral.
Statistical analysis
Meta-analysis was performed using the Stata/IC v.11 statis-
tical package (StataCorp LP, College Station, TX). Only
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those studies rated as good were included in the meta-
analysis. Studies with zero frequency were included in the
meta-analysis by entering 0.5 to zero cells so that all of the
information could be used.
The relative risk (RR) was calculated for these binary
outcomes (RR >1 indicates a positive effect of fluconazole).
We calculated the pooled relative risks with fixed effect
models using the Mantel and Haenszel method. The hetero-
geneity of the model was examined by calculating the
DerSimonian and Laird’s Q statistic [15] and the I2-
statistic [16]. Both were compared with a chi-square distri-
bution with degrees of freedom (df) equal to the number of
trials minus one. We used the Q statistic for testing the
presence of heterogeneity and the I2-statistic for estimating
the degree of heterogeneity. When heterogeneity was ob-
served, we used the with random effect models as suggested
by DerSimonian and Laird [15].
The forest plots have been created for presenting the
pooled effects of fluconazole. The effects of indication,
age groups, dose range, route of administration and duration
of treatment on risk of AEs in the fluconazole groups against
the active comparator were assessed using random effect
models.
Poisson regression analysis was used to test the effect of
indication, age groups, dose groups, route of administration
and duration of treatment on incidence of AEs and hepato-
toxicity in the fluconazole group. The incidence–rate ratios
(IRR) are reported from the Poisson regression analysis. All
results are reported with 95 % confidence intervals (CIs),
and all P values are two-tailed.
Results
Our search revealed 1,702 articles, of which 117 met our
inclusion criteria (Fig. 1). These were reduced to 90 follow-
ing assessment of data quality. Two articles in foreign lan-
guages (Chinese and Hebrew) were excluded because the
articles could not be translated. All 90 articles were pub-
lished between 1986 and 2011, and the most frequent type
of studies was the case report, followed by the case series
and the RCT (Table 1). Thirty-one (34 %) of the studies
involved neonates only.
The largest group of patients who received fluconazole
were taking part in RCTs (1,793 patients). These studies
compared fluconazole with griseofulvin, placebo, nystatin,
amphotericin B and other azole antifungals. One study
compared different routes of administration [17]. Seven of
the 14 RCTs were exclusively conducted in neonates (term
and preterm) [17–23], while the remainder involved chil-
dren across the paediatric age spectrum (birth–17 years)
[24–31]. Fluconazole was used as prophylaxis in six of the
eight neonatal RCTs.
The second largest group of patients on fluconazole
(1,564) were enrolled in cohort studies [32–38]. All cohort
study patients were preterm neonates, with fluconazole ad-
ministered either prophylactically orally or intravenously.
The other large group of patients (795) were in case series
[39–59]. Fifteen of these studies were conducted in term and
preterm neonates, while the others cut across the paediatric
age group. Seventy-seven patients were involved in eight
pharmacokinetic studies [60–67], three of which were per-
formed exclusively in preterm and term neonates.
Dosage and administration
Fluconazole was either administered as prophylaxis or ther-
apeutically. The median prophylactic dose was 3 mg/kg/day
[interquartile range (IQR) 3–6 mg/kg/day] over a median
period of 42 days (IQR 1.57–42 days). The median
administered therapeutic dose was 6 mg/kg/day (IQR 5–
6 mg/kg/day) over a median duration of 42 days (IQR 14–
67 days). Therapeutic indications were invasive candidiasis,
taenia capitis, fungal meningitis, urinary tract infection and
other mycotic infections. The duration of treatment ranged
between 1 day [40–42] and 9 years [68]. The most common
routes of administration were oral (30 %), IV (23 %) or both
(28 %) (Table 1).
Toxicity
A total of 4,209 patients from 90 studies were exposed to
fluconazole, with 794 AEs recorded in 35 studies. Hepato-
toxicity was the most common AE across all age groups.
About one-third of the reviewed articles exclusively in-
volved preterm and term neonates, accounting for 2,434
fluconazole exposed neonates. A total of 307 AEs
(38.6 %) were recorded in neonates, of which 295
(96.1 %) were hepatotoxic effects. Gastrointestinal events
were the second most common AE documented. One hun-
dred cases of respiratory symptoms were recorded in one
study, none of which was found to be drug-related. Other
adverse events identified were renal dysfunction, haemato-
logical abnormalities and rash (Table 2). The relative risk of
all AEs in the fluconazole group was not statistically differ-
ent from those treated with placebo (RR 1.30, 95 % CI
0.84–2.03, P=0.238). Compared to all other antifungal
drugs there was again no significant increase in the risk
(RR 1.05, 95 % CI 0.62–1.80, P=0.85) (Fig. 2a). The
overall relative risk of adverse events in the fluconazole
group was not significantly different within the treatment
group (RR 0.82, 95 % CI 0.49–1.36, P=0.437) or the
prophylaxis group (RR 1.68, 95 % CI 0.55–5.11, P=
0.364) compared to other antifungal drugs. There were
378 recorded cases of hepatotoxicity, accounting for just
under half of all the AEs across all age groups. The majority
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of cases (295) occurred in neonates. The relative risk of
hepatotoxicity with fluconazole was 1.36 (95 % CI 0.87–
2.14) and 1.43 (95 % CI 0.67–3.03) when compared with
placebo and other antifungals, respectively (Fig. 2a and 2b);
these relationships were not statistically significant (P=
0.175 and 0.352, respectively). However, when compared
against nystatin, the only comparator to have sufficient
numbers of patients for analysis, there was a significant
increase in risk of hepatotoxicity with fluconazole (RR
1.92, 95 % CI 1.13–3.26, P=0.016) (Fig. 2c).
Poisson regression analysis of the effect of treatment, age
group, dose, route of administration, indication and duration
of treatment on the incidence of hepatotoxicity of flucona-
zole was performed. This showed that the incidence of
hepatotoxicity with therapeutic fluconazole was significantly
greater than that with prophylaxis (IRR 5.34 95 % CI 1.99–
14.37, P=0.001), while the duration of treatment had no
effect. Although the incidence of hepatotoxicity in neonates
on fluconazole was greater than that in children (IRR 1.33,
95 % CI 0.63–2.80), this effect was not statistically signif-
icant (P=0.451). The incidence of hepatotoxicity appears to
decrease with increasing dose (IRR 0.52, 95 % CI 0.37–
0.74, P=0.001). Patients on oral fluconazole were less likely
to have hepatotoxicity than those on IV fluconazole
(IRR 0.21, 95 % CI 0.92–0.47, P=0.001).
Only three of the cohort studies reported any AE; one of
which was a prophylactic study which recorded 127 cases of
cholestasis in 409 fluconazole-exposed extremely low birth
weight neonates. However, this study did not report the
number of non-exposed neonates. Of these patients, 69 %
recovered, while the others were discharged or transferred to
other facilities [36]. Another prophylactic cohort study
recorded 60 cases of cholestasis in 140 fluconazole-exposed
extremely low birth weight neonates as against 12 in
137 non-exposed neonates (P<0.001) [34].
Of all the 378 hepatotoxicity cases, resolution of symp-
toms was not determined in 113 (30 %) cases, while in 42
(11 %) cases, all involving neonates, there was no improve-
ment at discharge or upon referral to another hospital (188
neonates and 35 children had completely recovered during
treatment or shortly after). Therefore, 84 % of patients, for
whom follow-up was complete, had resolution of symp-
toms. Hepatotoxicity was the most frequent reason for
withdrawal of the drug. Of the 41 drug-related with-
drawals,17 (42 %) were due to elevated liver enzymes
[26, 27, 30, 36, 42, 66, 69].
Gastrointestinal (GI) symptoms including nausea, vomit-
ing, abdominal pain, diarrhoea, dyspepsia, anorexia and
gastritis accounted for 15.4 % of AEs (122 cases) (Table 2).
There was only one recorded case of GI event in neonates.
MEDLINE-353 CINAHL-661 EMBASE-553 BIBLIOGRAPHY-95 COCHRANE-40
Search of Medline, Embase, CINAHL, Cochrane and bibliography of relevant articles  
yielded 1702 articles
1,220 articles excluded after 
screening for abstracts
478articles
447articles
334articlesexcluded because of 
lack of safety data and no 
documentation of number of 
patients.
2 articles in foreign languages 
could not be translated
31duplicates 
excluded
90 articles
5 RCTs, 1 cohort and 17 Case 
series were excluded after 
quality assessment
Fig. 1 Flow chart for articles
included in the systematic
review. CINAIL Cumulative
Index to Nursing and Allied
Health Literature, RCTs
randomised controlled trials
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There was no statistical difference in the risk of GI events of
fluconazole compared with placebo (RR 0.81, 95 %CI 0.12–
5.60, P=0.831). The risk of GI events increased, but not
significantly, when fluconazole was compared with other
comparator antifungal drugs (RR 1.23, 95 % CI 0.88–1.71,
P=0.235) and nystatin (RR 2.02, 95 % CI 0.66–6.23, P=
0.219). Poisson regression analysis showed that the inci-
dence of GI AEs were lower in neonates than children
(IRR 0.15, 95 % CI 0.03–0.66, p=0.012), while dose (IRR
1.07, 95 % CI 0.85–1.39, P=0.585) and duration of treat-
ment (IRR 1.01, 95 % CI 0.99–1.03, P=0.07) were unlikely
to significantly affect the incidence of GI events. Although
oral administration increased the incidence of GI AEs, this
increase was not significant (IRR 3.22, 95 % CI 0.72–14.33,
P=0.125).
There was a decrease in mortality when fluconazole was
compared with placebo, but this was not significant (RR
0.62, 95 % CI, 0.38–1.03, P=0.067). The mortality rate
between the fluconazole group and antifungal drugs was
not different (RR 1.01, 95 % CI 0.72–1.41, P=0.960)
(Table 3). No cases of drug-related death were documented.
There were ten reported cases of serious AEs, five of which
were not treatment-related [30]. The other serious AEs were
five drug interactions [70–74]. Two interactions in children
were with all-trans retinoic acid (ALTRA) and resulted in
acute renal failure and pseudotumour cerebri [70, 71]. An-
other case of acute renal failure in a 9-year-old child was
recorded following interaction with tacrolimus [73]. A 12-
year-old child had syncope following co-administration
Table 1 Summary of the 90 studies that reported on the safety of
fluconazole in paediatric populations included in this review
Characteristics of studies Number of
studies
Number of
patients
Type of study n=90 n=4,209
Case series 23 795
Case reports 38 65
RCT 14 1,793
Cohort studies 7 1,564
Pharmacokinetics studies 8 77
Route of Administration n=90 n=4,209
Oral 27 1,465
Intravenous and oral 26 1,602
Intravenous 21 971
Not reported 13 170
Intraperitoneal/rectal 3 15
Age groups n=90 n=4,209
Preterm neonates 20 2,354
Term neonates 7 43
Term and preterm neonates 4 37
Other paediatric age groupsa 59 1,775
RCT, Randomised controlled trial
a Including studies involving infants up to adolescence (some of which
included some neonates) and paediatric studies for which the age group
was not stated
Table 2 Reported adverse
events from 35 studies
GIT, Gastrointestinal tract
aNumber of adverse events
(AEs) cut across age categories
bObtained from a single study
cPatients with anorexia, gastritis,
dyspepsia, GI upset or a
combination of any of nausea,
vomiting, diarrhoea and
abdominal pain
Adverse events Preterm neonates
only
Term and preterm
neonates
Infancy–adolescence Othersa Total
Conjugated bilirubin 231 4 1 – 236
↑Liver enzymes 55 13 47 16 131
Respiratory infectionb – – 100 – 100
GIT symptomsc – – 55 – 55
Headache – – 24 – 24
Vomiting – 1 20 1 22
Abdominal pain – – 18 – 18
Other skin conditions – – 21 – 21
Rash/urticarial – – 19 – 19
Diarrhoea – – 16 1 17
Nausea – – 10 – 10
Eosinophilia – 6 1 1 8
Altered renal function – 3 4 – 7
Electrolyte derangement 2 – – – 2
Pruritus – – 6 – 6
Thrombocytopenia 5 – – – 5
Anaemia – 2 – – 2
Others – – 109 2 111
Total 293 29 451 21 794
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with amitriptyline [72]. Co-administration of fluconazole
with vincristine also caused severe constipation [74].
Discussion
Hepatotoxicity was the most frequent AE described in this
systematic review of the safety of fluconazole. It usually
manifested as conjugated hyperbilirubinaemia or deranged
liver enzymes and was also the most frequent reason for
withdrawal of fluconazole in both neonates and paediatric
patients. Our review demonstrated that over 80 % of the
cases with known outcomes had complete resolution during
treatment or after completion of therapy. Hepatotoxicity risk
was significantly greater in patients on fluconazole compared
with nystatin (p=0.016). The better safety of nystatin com-
pared with fluconazole has also been described by previous
authors [75]. There was an increased risk of hepatotoxicity
with fluconazole than placebo, but this increase was not
significant (p=0.175). Prematurity, total parenteral nutrition,
infection and congenital abnormalities are known risk factors
for hepatotoxicity in neonates [76]. More neonates than
Overall  (I-squared = 69.8%, p = 0.000)
Study
Hernandez-sampelayo et al 1994
Violaris et al 2009
Mondal et al 2004
Ninane et al 1994
Gupta et al 2001
Driessen et al 1996
Groll et al 1997
Aydemir et al 2012
Foster et al 2002
Flynn et al 1994
1.05 (0.62, 1.80)
RR (95% CI)
0.23 (0.03, 1.90)
0.08 (0.00, 1.33)
0.48 (0.05, 4.88)
1.82 (1.16, 2.85)
0.25 (0.01, 4.35)
0.39 (0.13, 1.15)
4.50 (1.77, 11.41)
1.01 (0.02, 50.41)
0.91 (0.79, 1.06)
1.77 (0.83, 3.76)
409.5/1375.5
Fluconazole
1/24
.5/38.5
1/22
45/245
.5/50.5
3/12
18/25
.5/93.5
323/771
17/94
Events,
199.5/1002.5
Comparator
4/22
7/42
2/21
26/257
6/150
7/11
4/25
.5/94.5
134/292
9/88
Events, Active
100.00
Weight
4.98
3.06
4.27
19.62
3.00
11.81
13.46
1.72
22.41
15.67
%
Favours Fluconazole  Favours Control 
1.01 100
Overall  (I-squared = 0.0%, p = 0.917)
Study
Manzoni et al 2007
Aydemir et al 2012
Kaufmann et al 2011
Kaufman et al 2001
1.36 (0.87, 2.14)
RR (95% CI)
1.36 (0.84, 2.22)
0.98 (0.02, 48.80)
2.61 (0.28, 24.09)
1.00 (0.21, 4.72)
56.5/405.5
Fluconazole
50/216
.5/93.5
Events,
3/46
3/50
22.5/287.5
Placebo
18/106
.5/91.5
Events,
1/40
3/50
100.00
Weight
84.07
1.76
%
3.72
10.44
Favours Fluconazole  Favours Placebo 
1.01 100
a
b
Fig. 2 a Fluconazole adverse
effects (AEs) compared to
those of other antifungals.
b Fluconazole hepatotoxicity
compared with that of placebo.
c Fluconazole hepatotoxicity
compared with that of nystatin
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children developed hepatotoxicity, even though this incidence
was not significantly different. Although animal studies have
demonstrated a dose-dependent histological evidence of hep-
atotoxicity [77], this review did not show any significant
effect of increasing dose on liver toxicity, probably because
most of the reviewed articles administered fluconazole within
the therapeutic dose limit of ≤12 mg/kg.
Our review also showed that GI events were the second
most common AE after hepatotoxicity; however, the relative
risk of this event is not statistically different between
patients on fluconazole and placebo or other antifungals.
There was just one recorded case of a GI AE in neonates.
This may be related to the fact that neonates are unable to
self- report these events, and GI events are less likely to be
identified by clinicians and parents. Nausea and abdominal
pain, for example, are extremely difficult, if not impossible
to detect in this age group.
Drug interactions with fluconazole have been docu-
mented. Fluconazole is a potent inhibitor of CYP enzymes
and is known to inhibit both CYP3A and CYP1A2 enzymes
[78]. Therefore, drug interactions with medicines such as
tacrolimus, vincristine, ALTRA, midazolam, caffeine and
amitriptyline are likely. Clinicians need to be aware of these
interactions and monitor for AEs.
The relatively small number of patients in several of the
groups for meta-analysis requires that these results be inter-
preted with caution. There were very few placebo controlled
RCTs—a pool of which involved fewer than 500 patients.
Such a small number may be insufficient to detect rare events.
Additionally, the majority of the RCTs are primarily efficacy
studies with poor and inconsistent reporting of safety out-
comes. We excluded about 25 % of the identified RCTs
because of their poor quality of safety reporting. Some of
these limitations were also identified in several studies evalu-
ating the quality of safety reporting in RCTs [79, 80]. Authors
often fail to indicate the severity of the AEs and, in several
cases, the relationship with medication was not determined. In
addition, the duration of observation and outcome of AEs
were often not established, with about 30 % of cases of
hepatotoxicity not followed up to identify whether resolution
had occurred. Comparison of fluconazole with other
Overall
Study
Groll et al 1997
Violaris et al 2009
Flynn et al 1994
Aydemir et al 2012
1.92 (1.13, 3.26)
RR (95% CI)
2.75 (1.01, 7.48)
2.05 (0.92, 4.60)
1.25 (0.45, 3.45)
1.01 (0.02, 50.41)
32.5/250.5
Fluconazole
Events,
11/25
13/38
8/94
.5/93.5
17.5/249.5
Nystatin
Events,
4/25
7/42
6/88
.5/94.5
100.00
Weight
%
28.00
43.07
27.09
1.84
Favours Fluconazole  Favours Nystatin 
1.01 100
c
Fig. 2 (continued)
Table 3 Effect of fluconazole compared with placebo, nystatin and
active comparator
Relative risk 95 % confidence
interval
P value
Placebo
Hepatotoxicity 1.37 0.87–2.14 0.175
GI events 0.81 0.12–5.59 0.831
Mortality 0.62 0.37–1.03 0.067
Withdrawal due to AE 0.78 0.08–7.24 0.828
Other antifungals
Hepatotoxicity 1.43 0.67–3.03 0.352
GI events 1.23 0.88–1.71 0.235
Mortality 1.01 0.72–1.41 0.960
Withdrawal due to AE 1.25 0.62–2.53 0.534
Nystatin
Hepatotoxicity 1.92 1.13–3.26 0.016*
GI events 2.02 0.66–6.23 0.219
Mortality 1.01 0.02–50.41 0.825
Withdrawal due to AE 1.01 1.11–9.59 0.992
* (<0.05) statistically significant
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antifungal agents, except nystatin, was also impossible be-
cause of the paucity of good quality studies. Further research
should include studies with extended follow-up to capture
data regarding the resolution of hepatotoxicity, especially in
the neonatal population.
In conclusion, fluconazole is relatively safe for paediatric
patients. Hepatotoxicity and GI events are the most common
AEs. It is important to be aware that drug interactions with
fluconazole can result in significant toxicity [81–111].
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